NuCana plc

NasdaqCM:NCNA Voorraadrapport

Marktkapitalisatie: US$3.5m

NuCana Beheer

Beheer criteriumcontroles 3/4

NuCana's CEO is Hugh Griffith, appointed in Mar 2008, has a tenure of 16.67 years. total yearly compensation is £974.59K, comprised of 58.9% salary and 41.1% bonuses, including company stock and options. directly owns 2.25% of the company’s shares, worth $77.93K. The average tenure of the management team and the board of directors is 4.1 years and 6.5 years respectively.

Belangrijke informatie

Hugh Griffith

Algemeen directeur

UK£974.6k

Totale compensatie

Percentage CEO-salaris58.9%
Dienstverband CEO16.7yrs
Eigendom CEO2.3%
Management gemiddelde ambtstermijn4.1yrs
Gemiddelde ambtstermijn bestuur6.5yrs

Recente managementupdates

Recent updates

Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?

Aug 21
Can NuCana (NASDAQ:NCNA) Afford To Invest In Growth?

Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

Mar 14
Here's Why NuCana (NASDAQ:NCNA) Must Use Its Cash Wisely

We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

Oct 15
We're Keeping An Eye On NuCana's (NASDAQ:NCNA) Cash Burn Rate

Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation

Jul 01
Here's Why We're A Bit Worried About NuCana's (NASDAQ:NCNA) Cash Burn Situation

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Mar 15
Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

Nov 30
Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

NuCana: An Intriguing 'Sum Of The Parts' Story

Sep 22

NuCana GAAP EPS of -£0.07

Aug 17

NuCana regains Nasdaq compliance

Jul 27

NuCana: Improving Chemotherapy And A Major Patent Litigation Win Against Gilead

Jul 13

Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

May 02
Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation

We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

Jan 17
We Think NuCana (NASDAQ:NCNA) Can Easily Afford To Drive Business Growth

NuCana: Preparing For A Critical 2022

Dec 08

We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

Sep 30
We're Interested To See How NuCana (NASDAQ:NCNA) Uses Its Cash Hoard To Grow

NuCana: The Market Continues To Overlook Its ProTide Platform Technology

Sep 11

We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Jun 01
We Think NuCana (NASDAQ:NCNA) Can Afford To Drive Business Growth

Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

Feb 15
Companies Like NuCana (NASDAQ:NCNA) Are In A Position To Invest In Growth

How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

Dec 22
How Many NuCana plc (NASDAQ:NCNA) Shares Do Institutions Own?

NuCana (NCNA) Investor Presentation - Slideshow

Dec 02

NuCana reports Q3 results

Nov 19

Analyse CEO-vergoeding

Hoe is Hugh Griffith's beloning veranderd ten opzichte van NuCana's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-UK£28m

Mar 31 2024n/an/a

-UK£27m

Dec 31 2023UK£975kUK£574k

-UK£28m

Sep 30 2023n/an/a

-UK£35m

Jun 30 2023n/an/a

-UK£33m

Mar 31 2023n/an/a

-UK£31m

Dec 31 2022UK£1mUK£552k

-UK£32m

Sep 30 2022n/an/a

-UK£30m

Jun 30 2022n/an/a

-UK£34m

Mar 31 2022n/an/a

-UK£39m

Dec 31 2021UK£907kUK£531k

-UK£41m

Sep 30 2021n/an/a

-UK£39m

Jun 30 2021n/an/a

-UK£40m

Mar 31 2021n/an/a

-UK£36m

Dec 31 2020UK£920kUK£551k

-UK£31m

Sep 30 2020n/an/a

-UK£26m

Jun 30 2020n/an/a

-UK£22m

Mar 31 2020n/an/a

-UK£20m

Dec 31 2019UK£828kUK£498k

-UK£21m

Sep 30 2019n/an/a

-UK£17m

Jun 30 2019n/an/a

-UK£16m

Mar 31 2019n/an/a

-UK£13m

Dec 31 2018UK£786kUK£467k

-UK£14m

Sep 30 2018n/an/a

-UK£15m

Jun 30 2018n/an/a

-UK£26m

Mar 31 2018n/an/a

-UK£28m

Dec 31 2017UK£635kUK£330k

-UK£23m

Compensatie versus markt: Hugh's total compensation ($USD1.26M) is above average for companies of similar size in the US market ($USD655.65K).

Compensatie versus inkomsten: Hugh's compensation has been consistent with company performance over the past year.

CEO

Hugh Griffith (56 yo)

16.7yrs

Tenure

UK£974,586

Compensatie

Mr. Hugh Stephen Griffith is Founder of NuCana plc (formerly, NuCana BioMed Limited) and has been its Chief Executive Officer since March 2008. Mr. Griffith was also the Chief Executive Officer at Alida Ca...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Hugh Griffith
Founder16.7yrsUK£974.59k2.25%
$ 77.9k
Donald Munoz
Chief Financial Officer9.1yrsgeen gegevens0.28%
$ 9.5k
David Harrison
Head of Translational Medicine6.9yrsgeen gegevens0%
$ 0
Jeffrey Bloss
Chief Medical Officer3.3yrsgeen gegevens0.00018%
$ 6.2
Theresa Bruce
Senior Vice President of Clinical Operations4.8yrsgeen gegevensgeen gegevens
Elisabeth Oelmann
Senior Vice President of Medical & Clinical Development4.1yrsgeen gegevensgeen gegevens
John-Paul Gallivan
Senior VP of Strategy & Lifecycle Managementless than a yeargeen gegevensgeen gegevens
Gordon Kennovin
Senior VP of CMC & Developmentless than a yeargeen gegevensgeen gegevens
Stuart Grant
Senior Vice President of Regulatory Affairsless than a yeargeen gegevensgeen gegevens
Martin Quinn
Company Secretaryno datageen gegevensgeen gegevens

4.1yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: NCNA's management team is considered experienced (4.1 years average tenure).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Hugh Griffith
Founder16.7yrsUK£974.59k2.25%
$ 77.9k
Andrew Kay
Independent Non-Executive Chairman3.9yrsUK£78.77k0%
$ 0
Martin Mellish
Independent Non-Executive Director14.9yrsUK£47.85k0.050%
$ 1.7k
Adam George
Independent Non Executive Director6.6yrsUK£56.56k0%
$ 0
Balaji Muralidhar
Independent Non-Executive Director4.2yrsUK£29.25k0.00098%
$ 33.9
Elliott Levy
Independent Director3yrsUK£54.23k0.0084%
$ 289.6
Cyrille Leperlier
Independent Non Executive Director6.5yrsUK£65.08k0%
$ 0

6.5yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: NCNA's board of directors are considered experienced (6.5 years average tenure).